Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Goodwill (2016 - 2025)

Historic Goodwill for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $13.9 million.

  • Lifecore Biomedical, Inc. \De\'s Goodwill changed 0.0% to $13.9 million in Q2 2025 from the same period last year, while for May 2025 it was $13.9 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $13.9 million for FY2025, which is 0.0% changed from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s Goodwill stood at $13.9 million, which was down 0.0% from $13.9 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Goodwill registered a high of $13.9 million during Q2 2022, and its lowest value of $13.9 million during Q1 2021.
  • Moreover, its 5-year median value for Goodwill was $13.9 million (2021), whereas its average is $13.9 million.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s Goodwill plummeted by 8203.01% in 2021 and then increased by 13.69% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Goodwill (Quarter) stood at $13.9 million in 2021, then changed by 0.0% to $13.9 million in 2022, then changed by 0.0% to $13.9 million in 2023, then changed by 0.0% to $13.9 million in 2024, then changed by 0.0% to $13.9 million in 2025.
  • Its Goodwill stands at $13.9 million for Q2 2025, versus $13.9 million for Q1 2025 and $13.9 million for Q4 2024.